Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor combined with cytotoxic chemotherapy is highly effective for the treatment of advanced non–small-cell lung cancer (NSCLC) with EGFR ...

Twenty years after the epidermal growth factor receptor (EGFR) was identified as a potential anticancer target, the EGFR inhibitor gefitinib (Iressa; AstraZeneca) has been approved for the treatment ...

Consistent with previous observations, overall survival and progression-free survival remained strong at the follow-up point. The phase 3 trial found that adding chemotherapy to gefitinib improved PFS ...

Non–small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about ...

Learn everything you need to know about Gefitinib-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Gefitinib is an orally active inhibitor of tyrosine kinase epidermal growth factor, 1 with clinical effectiveness in the control of non–small-cell lung cancer. We describe 3 patients with possible ...

The Appraisal Committee considered evidence submitted by the manufacturer of gefitinib and a review of this submission by the Evidence Review Group (ERG). The manufacturer's decision problem compared ...

MANILA, Philippines - Research-based pharmaceutical company AstraZeneca’s targeted cancer therapy gefitinib has received approval from the Philippine Food and Drug Administration (FDA) as first-line ...

Details concerning the Gefitinib medication encompass its pricing as well as its availability in various forms, including tablets, capsules, syrups, creams, gels, ointments, liquids, and injections.

The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of gefitinib for locally advanced or metastatic NSCLC, having considered evidence on the nature of locally ...